22 September 2020
Permira funds to acquire leading European CNS specialty pharmaceutical company Neuraxpharm
Permira, the global private equity firm, today announced that a company backed by the Permira funds has agreed to acquire Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS) from Apax Partners. Financial details of the transaction were not disclosed.
With its unique understanding of the CNS market built over 35 years, Neuraxpharm develops and commercializes value-added medicines and consumer healthcare products for chronic patients suffering from neurological and psychiatric disorders including Epilepsy, Parkinson’s, Alzheimer’s, Depression and Psychosis. With one of the broadest and most diversified product portfolios in the market, its strong medical reputation and CNS expertise, the company enjoys leading positions in its core markets Germany and Spain, with a #1 position across Europe in many of its more than 115 CNS molecules. Neuraxpharm is one of the fastest growing specialty pharmaceutical companies in Europe, driven by the successful launch of new value-added medicines and a strong M&A track-record. Today, Neuraxpharm has annual revenues in excess of €460 million and more than 850 employees. Closing of the transaction is subject to customary closing conditions and is expected in the fourth quarter of 2020.